Verus Capital Partners LLC Has $228,000 Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Verus Capital Partners LLC lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 320 shares of the biopharmaceutical company’s stock after selling 20 shares during the period. Verus Capital Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $228,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in REGN. Focus Financial Network Inc. grew its position in Regeneron Pharmaceuticals by 7.4% in the 3rd quarter. Focus Financial Network Inc. now owns 538 shares of the biopharmaceutical company’s stock worth $566,000 after purchasing an additional 37 shares in the last quarter. Americana Partners LLC bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth about $330,000. Farther Finance Advisors LLC grew its position in Regeneron Pharmaceuticals by 7.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 724 shares of the biopharmaceutical company’s stock worth $761,000 after purchasing an additional 53 shares in the last quarter. Empire Life Investments Inc. bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth about $5,030,000. Finally, Van ECK Associates Corp grew its position in Regeneron Pharmaceuticals by 8.9% in the 3rd quarter. Van ECK Associates Corp now owns 58,136 shares of the biopharmaceutical company’s stock worth $61,115,000 after purchasing an additional 4,742 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $698.74 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The stock has a market capitalization of $76.39 billion, a PE ratio of 18.25, a P/E/G ratio of 2.34 and a beta of 0.08. The company’s 50 day simple moving average is $698.51 and its two-hundred day simple moving average is $868.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the prior year, the company posted $11.86 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.50%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Citigroup reduced their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. BMO Capital Markets reduced their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research report on Tuesday, February 4th. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Sanford C. Bernstein reduced their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Finally, Wells Fargo & Company reduced their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.